Clinical trials: Vaccine Effectiveness Against COVID-19
Immunogenicity, Safety
A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2
Primary Immunogenicity Objective：Cohort 1: GMTs of SARS-CoV-2 Omicron and related strain neutralizing antibody levels for SWIM816.Cohort 2: To demonstrate the non- inferiority of neutralizing antibody response in terms of…
- Trial name
- NCT05911087
- Testing
- Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2;
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
COVID-19, Sars-CoV-2 Infection
Phase 3 Booster Vaccination Against COVID-19
The inactivated Booster Phase 3 study aims to determine the efficacy, safety, and immunogenicity of inactivated COVID-19 vaccines in subjects with a minimum of 90 days and a maximum of 270 days after the second dose of CoronaVac…
- Trial name
- NCT05077176
- Testing
- CoronaVac, Turkovac
- Where
- 41 sites in Turkey (Türkiye)
- Volunteers
- 4,340 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
COVID-19, Vaccine Adverse Reaction
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
The objective of this observational case-crossover study is to evaluate the effectiveness, safety and immunogenicity of the second booster dose in the elderly.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases
- Trial name
- Plus_Booster (NCT05283902)
- Testing
- ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine
- Where
- Brazil
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Federal University of Espirito Santo
Covid19
Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus
Randomized, double-blind (blinded for the trial subject and the study physician), placebo controlled, multi-center clinical trial in parallel assignment of efficacy, immunogenicity, and safety of the Gam-COVID-Vac combined vector…
- Trial name
- NCT04564716
- Testing
- Gam-COVID-Vac
- Where
- 8 sites in Belarus
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID-19, Sars-CoV-2 Infection
Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent
This study is a multi-center, randomized, national, observer-blinded, active-controlled phase IIB clinical trial to determine the efficacy, immunogenicity, and safety of two-doses of inactive COVID-19 vaccine (TURKOVAC) vaccine…
- Trial name
- NCT05230940
- Testing
- TURKOVAC, CoronaVac
- Where
- 14 sites in Turkey (Türkiye)
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
Heart Transplantation, COVID-19 Virus Infection
Covid-19 Vaccine Response in Heart Transplant Recipients
Clinical studies indicate a decrease in vaccine efficacy in certain immunocompromised populations (kidney transplant recipients, patients undergoing chemotherapy).
- Conditions
- Heart Transplantation, COVID-19 Virus Infection, COVID-19 Vaccine
- Trial name
- COVHEART (NCT05268679)
- Testing
- Biospecimen Collection, Questionnaire, Electronic Health Record Review
- Where
- France
- Volunteers
- 190 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection.
- Trial name
- DAN-COVID (NCT07279766)
- Testing
- mRNA-1273 (Moderna COVID-19 vaccine)
- Where
- 2 sites in Denmark
- Volunteers
- 41,060 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Coronavirus
Investigating a Vaccine Against COVID-19
A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.
- Trial name
- NCT04400838
- Testing
- ChAdOx1 nCoV-19 (Abs 260), MenACWY vaccine, ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost
- Where
- 20 sites in United Kingdom
- Volunteers
- 10,811 people, healthy volunteers welcome
- Sponsor
- University of Oxford
COVID-19
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a…
- Trial name
- VAT00008 (NCT04904549)
- Testing
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
- Where
- 86 sites in United States, Colombia and 9 more
- Volunteers
- 23,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, SARS CoV 2 Infection
Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Pregnant Women
This study is an open-label and Phase 2b clinical trial of the COVID-19 inactivated TURKOVAC vaccine against SARS-CoV-2 in healthy pregnant women.
- Trial name
- NCT06997653
- Testing
- TURKOVAC
- Where
- Turkey (Türkiye)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
Neuromuscular Diseases, COVID-19
Efficacy of Vaccination Against COVID-19 in Patients Presenting a Neuromuscular Disease With Severe Amyotrophy
Des vaccins sont désormais disponibles en France, dont le vaccin Moderna COVID-19 qui est basé sur la technologie des ARNm. La séquence génétique qu'il contient code pour la protéine Spike (S) de l'enveloppe virale, protéine clé…
- Conditions
- Neuromuscular Diseases, COVID-19, Amyotrophy
- Trial name
- CANNEMUSS (NCT05353738)
- Testing
- Blood sample for research of anti-xoprs netralizing anti spike, Questionnaire
- Where
- France
- Volunteers
- 36 people
- Sponsor
- University Hospital, Bordeaux
COVID-19
Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.
IIBR-100 (VSV-ΔG) is a self-propagating live virus vaccine that contains the spike protein of the Wuhan wild-type SARS-CoV-2 virus.
- Trial name
- BRILIFE002 (NCT04990466)
- Testing
- IIBR-100, Active Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- NeuroRx, Inc.
Immunogenicity, Safety
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
Primary#Objectives #Immunogenicity:To demonstrate the non-inferiority of binding antibody response in terms of geometric mean titers (GMT) of mRNA vaccine compare with mRNA COVID-19 vaccine(Pfizer) 14 days post dose.
- Conditions
- Immunogenicity, Safety, Efficacy
- Trial name
- NCT05686161
- Testing
- SW-BIC-213;SARS-Cov-2., Sinopharm (BIBP);SARS-Cov-2., Pfizer(BNT162b2);SARS-Cov-2.
- Where
- Laos
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
Covid19
Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela
Randomized, double-blind, placebo controlled clinical trial of immunogenicity, safety and efficacy of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults.
- Trial name
- VENEZUELA (NCT04642339)
- Testing
- Gam-COVID-Vac
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
SARS-CoV-2 Infection, COVID-19
To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
Substudy A: The study will evaluate the safety, tolerability, and efficacy of a booster dose of BNT162b2 when administered to participants having previously received 2 doses of BNT162b2 at least 6 months prior to randomization.
- Trial name
- NCT04955626
- Testing
- BNT162b2, BNT162b2 OMI, Combination BNT162b2 and BNT162b2 OMI
- Where
- 154 sites in United States, Brazil and 3 more
- Volunteers
- 16,372 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV-2 Infection, COVID-19
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.
- Trial name
- NCT04368728
- Testing
- BNT162b1, BNT162b2, BNT162b2SA
- Where
- 175 sites in United States, Argentina and 4 more
- Volunteers
- 46,969 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 Vaccines
Effectiveness of Vaccination Against COVID-19 in Brazil: Case-Control Study
The main objective of the study is to evaluate the effectiveness of the vaccine against covid-19, recommended by the national immunization program. This is a multicentric, observational, case-control study.
- Trial name
- NCT05621928
- Where
- Brazil
- Volunteers
- 3,920 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Covid19
Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity
This is a quasi-experimental study with risk-based allocation. Public security and education professionals from the state government will be included.
- Trial name
- COVACMANAUS (NCT04789356)
- Testing
- Adsorbed SARS-CoV-2 (inactivated) vaccine
- Where
- Brazil
- Volunteers
- 6,233 people, healthy volunteers welcome
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Influenza
An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older
The primary efficacy objective is to demonstrate the efficacy of aCoV2 versus a placebo to prevent the first occurrence of virologically-confirmed symptomatic COVID 19 according to the European Centre for Disease Prevention and…
- Trial name
- NCT04806529
- Testing
- Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2), Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seqirus
Covid19
Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults
This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first…
- Trial name
- COVID-19 (NCT04866069)
- Testing
- SARS-CoV-2 vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Osman ERGANIS, PhD, Prof